Merck KGaA
Merck KGaA, Nerviano Enter License Agreement for PARP1 Inhibitor NMS-293
The two firms will initially collaborate on development of the drug for the treatment of glioblastoma and BRCA1/2-mutant solid tumors.
Transcriptomics Plus 'Immune Tolerance' of Normal Tissue Shows Promise in Lung Cancer Prognosis
Premium
The WIN Consortium has further validated its DDPP algorithm in a recently published study and shown for the first time that biomarkers gleaned from normal tissue can be clinically informative, too.
Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC Patients
Premium
Studies at ESMO showed the importance of repeat biomarker testing to guide treatment after resistance to AstraZeneca's Tagrisso, but tissue-based testing remains a hindrance.
BMS, Merck KGaA Partner with Amphista Therapeutics to Develop Targeted Protein Degraders
The company will use its Eclipsys platform to develop protein degrader therapies for the treatment of cancer and immuno-inflammatory diseases for BMS and Merck KGaA.
NICE Recommends Merck's Tepmetko for NSCLC Patients With METex14 Skipping Mutation
More than 700 people in England are now eligible to receive Tepmetko as either a first- or second-line treatment.